

Prof. Dr. Jörn Schattenberg



Director Department of Medicine Internal Medicine II, Saarland University, Medical Center and Saarland University Faculty of Medicine

Role in LiSyM-Cancer

- Partner in SMART-NAFLD
- Prospective collection of tissue samples and medical imaging
- Access to serum samples from patients with MASLD

Expertise

- Development of new diagnostic and therapeutic approaches for liver diseases
- Development of new concepts for the early detection, prevention and treatment of metabolic liver diseases
- Metabolic-dysfunction associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD)

Degrees

- 2023 Full Professor (Saarland University)
- 2019 Associate Professor of Internal Medicine (APL; University Medical Center Mainz)
- 2013 Assistant Professor (Venia legendi, Internal Medicine)
- 2002 Medical License (MD) and Medical degree (Promotion; Dr. med.)

Professional Experience

- Since 2023 Director Department of Internal Medicine II, Saarland University Medical Center Homburg (Germany)
- 2021-2023 Co-Deputy Director, I. Department of Medicine, University Medical Center Mainz (Germany)
- 2017-2023 Head of Hepatology outpatient and clinical trial unit, I. Department of Medicine, Mainz (Germany)
- Since 2013 Head of translational Hepatology (research laboratory and clinical trials)
- 2011 Board Certification, Gastroenterology and Hepatology (Germany)
- 2010 Board Certification, Internal Medicine (Germany)

Honors and Awards (selection)

- 2014 Walter-Krienitz-Gedenkpreis der DGVS; Arbeit zu Magenkarzinomen
- 2012 Annual price German Association for the Study of Liver Disease (GASL) der YAEL-Stiftung
- 2008 Annual price Gastroenterologischen Arbeitsgesellschaft Rheinland-Pfalz Saarland (GARPS)

Publications

2023-08-03	Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients <i>Liver International</i>
2023-08-01	Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study <i>The Lancet</i>
2022-08-01	Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4 <i>Journal of Clinical Medicine</i>
